{"id":"NCT00722566","sponsor":"Millennium Pharmaceuticals, Inc.","briefTitle":"A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma","officialTitle":"An Open-Label Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2010-08","completion":"2010-09","firstPosted":"2008-07-25","resultsPosted":"2011-10-04","lastUpdate":"2011-10-10"},"enrollment":222,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"VELCADE Administered by subcutaneous injection","otherNames":[]},{"type":"DRUG","name":"VELCADE Administered by intravenous infusion","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"Randomized, open-label, international, multi-center, Phase 3 study in which patients are randomized to receive VELCADE administered by subcutaneous injection or intravenous infusion.","primaryOutcome":{"measure":"Number of Patients With Overall Response (Complete Response + Partial Response)","timeFrame":"Over 4 cycles (prior to the addition of dexamethasone)","effectByArm":[{"arm":"VELCADE Subcutaneuous","deltaMin":61,"sd":null},{"arm":"VELCADE Intravenous","deltaMin":31,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00201"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Belgium","France","Germany"]},"refs":{"pmids":["25596270","21507715"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":147},"commonTop":["Leukopenia","Constipation","Fatigue","Insomnia","Weight decreased"]}}